Occasionally, we schedule our rounds with Healthcare Brew readers. Want to be featured in an upcoming edition? Click here to introduce yourself.
Jayme Strauss is the chief commercial and clinical officer of brain implant (called a brain-computer interface, or BCI) manufacturer Precision Neuroscience, which helps patients with paralysis do things like operate a phone or robotic limb through their thoughts.
“It sounds like science fiction, but it’s real,” she told Healthcare Brew, as she explained what the company is working on.
In the role, Strauss shared she works with multiple bodies to ensure this tech reaches patients: from the doctors performing surgery to the FDA to the researchers and engineers creating the devices to the insurers covering the procedures.
We spoke with Strauss about what led her to the role, what she finds most fulfilling, and where she’s feeling most optimistic.
This interview has been edited for length and clarity.
How did you find yourself in this role?
This is personal for me. I’ve worked as a neuroscience critical care nurse, led hospital teams, and I have watched people I love face diseases like ALS and spinal cord injury. I know what it means when someone loses the ability to move or speak and how powerful it would be to give some of that independence back. My “why” isn’t just about cool tech—it’s about giving people a voice, control, and a way to connect with the world and their loved ones.
What’s the best change you’ve made or seen at a place you’ve worked?
In the early stages, much of our energy was devoted to validating the safety and performance of our BCI system. That work was essential. But once we proved the science, we asked ourselves: How do we build trust, not just technology? That question led us to bring in broader voices. Working side by side with these stakeholders, especially in partnerships with the FDA, has allowed us to address critical issues early on, from data privacy and interoperability to ethics and access.
Navigate the healthcare industry
Healthcare Brew covers pharmaceutical developments, health startups, the latest tech, and how it impacts hospitals and providers to keep administrators and providers informed.
Clinically, we’ve now worked with nearly 60 patients across leading institutions. By integrating direct feedback from neurosurgeons, patients, caregivers, and care teams into our development process, we have refined our protocols to address real-world needs.
At the end of the day, it is not enough to just build the technology. It’s about ensuring that what we build is ethical, human-centered, and accessible.
What’s the most fulfilling aspect of your job?
I came to this work not just as a healthcare leader, but as a daughter-in-law, a niece, and a caregiver. I lost my father-in-law to ALS. I have watched my uncle adjust to life with quadriplegia after a spinal cord injury. I’ve seen, up close, the way loss of independence ripples outward, impacting not just the person but their family, their identity, and their future.
Every day, I get to sit at the intersection of research, clinical practice, and commercial strategy, helping translate this life-changing technology into something that can reach the people who need it most. It’s about solving hard problems and never forgetting who we’re solving them for.
In a world where too many patients are told, “There’s nothing more we can do,” I’m proud to be part of a team working to change that answer.
What healthcare trend are you most optimistic about?
I’m most optimistic about the convergence of AI and medical devices, especially in brain-related conditions. We’re only beginning to scratch the surface of what’s possible when we pair neural data with intelligent systems.